Euro Pacific upgrades Sophiris Bio to buy

Sophiris Bio

Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in benign prostatic hyperplasia (BPH).

Shares of Sophiris closed at $2.90 on Tuesday after jumping $2.04 on the news.

Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.”

The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added.

Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.